# DESCRIPTION

## FIELD OF THE INVENTION

- relate to bone morphogenetic proteins

## BACKGROUND OF THE INVENTION

- describe bone morphogenetic proteins and their functions

## SUMMARY OF THE INVENTION

- provide designed bone morphogenetic proteins
- provide designed BMPs with reduced susceptibility to inhibition
- provide nucleic acid sequences encoding designed BMPs
- provide chimeric proteins with TGF-beta superfamily protein and wild-type BMP-6
- provide chimeric proteins with TGF-beta superfamily protein and wild-type BMP-9
- provide modified BMPs or GDFs with reduced inhibition by Noggin or Noggin-like proteins
- provide modified BMP-2 with amino acid substitutions
- provide modified BMP-4 with amino acid substitutions
- provide modified BMP-5, BMP-7, GDF-5, GDF-6, and GDF-7 with amino acid substitutions

## DETAILED DESCRIPTION OF THE INVENTION

- introduce modified BMPs with improved properties

### Bone Morphogenetic Proteins

- define BMP subfamily and TGF-Î² superfamily
- describe BMP structure and signal transduction

### Interactions Between BMPs and Their Antagonists

- describe BMP-Noggin interactions
- motivate Noggin function in development
- introduce BMP-6 and BMP-9 resistance to Noggin
- describe modified BMP-7 proteins with Noggin resistance
- list specific amino acid substitutions for Noggin resistance
- describe modified BMP-7
- describe modified BMP-2
- describe modified BMP-4
- describe modified BMP-5
- describe modified GDFs
- describe modified BMPs with middle region of BMP-9
- generalize modifications to other BMP subfamily members

### Generating Modified BMPs

- define modified BMPs
- describe properties of modified BMPs
- specify identity with wild-type BMP protein sequence

### Preparing Nucleic Acids Encoding Modified BMPs

- prepare nucleic acids encoding modified BMPs

### Expression Vectors

- describe expression vectors for modified BMPs

### Transfection/Transformation

- introduce modified BMP nucleic acids into host cells

### Hosts for Expression of Modified BMPs

- list hosts for expression of modified BMPs

### Expression Methods

- produce modified BMPs by culturing host cells

### Purification

- define purification methods
- introduce chromatographic techniques
- describe ultrafiltration and diafiltration
- discuss degree of purification
- provide reference for purification techniques
- describe animal models of BMP activity
- describe formulation and administration of designed BMPs
- describe pharmaceutical compositions of designed BMPs
- describe therapeutic uses of modified BMPs
- describe treatment of metabolic bone diseases
- describe periodontal tissue regeneration
- describe liver regeneration
- describe treatment of chronic renal failure
- describe other therapeutic uses of modified BMPs

## EXAMPLES

### BMP Induction of Alkaline Phosphatase Activity

- test BMPs for ALP activity

### Noggin Inhibition of a Panel of Exemplary BMPs and Related Proteins

- test Noggin inhibition of BMPs
- calculate IC50 for Noggin inhibition

### BMP-6 Induction of Downstream Genes in Primary Human Bone Marrow-Derived Mesenchymal Stem Cells is Less Susceptible to Noggin Inhibition

- test BMP-6 induction of downstream genes

### BMP-7 Variant Proteins with Marked Resistance to Noggin Inhibition

- engineer BMP-7 variants with BMP-6 sequences
- test susceptibility to Noggin inhibition
- identify residues responsible for noggin resistance

### Example 5

- identify residues differing between BMP-6 and BMP-7
- mutate residues in BMP-7 to corresponding residues in BMP-6
- test mutants for noggin resistance
- identify lysine 60 as critical for noggin resistance
- test BMP-7 E60K for noggin resistance
- introduce lysine residue into BMP-2 sequence
- test BMP-2 P36K for noggin resistance
- generate additional mutants with point mutations
- test mutants for noggin resistance
- identify residues beyond lysine 60 that confer noggin resistance
- test mutants without mutations at position 60 for noggin resistance

